Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Kern

Clinical Nurse Specialist, Family Health Kingman, AZ Nurse Practitioner

NPI 1992113906 CMS profile 11109021

1858 Golden Gate Ave, Kingman, AZ 86401

Open in the dashboard

General payments

$984

47 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Kern of Kingman, AZ is reported in the CMS Open Payments database as having received $984 across 47 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Clinical Nurse Specialist, Family Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $101 6
2024 General $156 9
2023 General $529 19
2022 General $185 12
2021 General $14 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Kern
  • Clinical Nurse Specialist, Family Health median
  • Middle half of Clinical Nurse Specialist, Family Health
  • National median

In program year 2025, general payments to Jennifer Kern were reported at $101. Among 164 Clinical Nurse Specialist, Family Health profiles paid that year, the median was $216 and the middle half received between $57 and $492.

Show as a table
Year Jennifer Kern Clinical Nurse Specialist, Family Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $14 $151 $46–$400 $132
2022 $185 $153 $37–$527 $149
2023 $529 $139 $50–$451 $160
2024 $156 $150 $46–$571 $164
2025 $101 $216 $57–$492 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Astellas Pharma US Inc $229 6 payments
  2. Exact Sciences Corporation $142 8 payments
  3. Lilly USA, LLC $138 8 payments
  4. Novo Nordisk Inc $116 7 payments
  5. Amgen Inc. $104 7 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $89 1 payment
  7. Biohaven Pharmaceutical Holding Company Ltd. $35 2 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $31 2 payments
  9. Galderma Laboratories, L.P. $19 1 payment
  10. AstraZeneca Pharmaceuticals LP $19 1 payment
  11. Other $63 4 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $965 46 payments
  2. Education $19 1 payment
Products named General payments · program years 2021–2025
  1. Veozah $206 5 payments
  2. Cologuard Collection Kit $142 8 payments
  3. Wegovy $100 6 payments
  4. JARDIANCE Diabetes $89 1 payment
  5. JARDIANCE Diabetes $84 5 payments
  6. EVENITY $59 4 payments
  7. Prolia $59 4 payments
  8. MOUNJARO $54 3 payments
  9. Otezla $45 3 payments
  10. Repatha $45 3 payments
  11. Other $267 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 122 drugs

Part D claims

6,331

Median for Nurse Practitioner: 389

Drug cost

$449,188

Median for Nurse Practitioner: $21,885

Branded share of claims

17.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 61 $102,142
Mounjaro Tirzepatide Brand 49 $88,038
Jardiance Empagliflozin Brand 44 $59,316
Eliquis Apixaban Brand 32 $48,162
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 20 $25,239
Breo Ellipta Fluticasone/Vilanterol Brand 15 $16,917
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 30 $8,955
Advair Hfa Fluticasone Propion/Salmeterol Brand 12 $8,211
Symbicort Budesonide/Formoterol Fumarate Brand 12 $6,939
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 21 $5,505

The 10 drugs with the highest cost, of 122 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$24,021

Of which drugs: $88

Medicare patients

216

Average age 74

Services billed

681

142 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 40%
Diabetes 31%
Chronic kidney disease 25%
Ischemic heart disease 23%
COPD 16%
Depression 16%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 16 74 $50
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 17 55 $37

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $36
$36 — —
Veozah
  • Astellas Pharma US Inc $17
$17 — —
EVENITY
  • Amgen Inc. $15
$15 — —
Prolia
  • Amgen Inc. $15
$15 — —
ZEPBOUND
  • Lilly USA, LLC $11
$11 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

47 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Family Health in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record